Completed PHASE4 INTERVENTIONAL 1-arm NCT00224289

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma

Sponsor: Pfizer

Conditions Glaucoma

Updated 8 times since 2017 Last updated: Nov 9, 2012 Started: Mar 31, 2005 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Glaucoma and is currently completed. Pfizer leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States